CJC-1295 Half-Life: Pharmacokinetics from Published Studies

Scientist working at a laboratory — CJC-1295 half-life pharmacokinetics research

The CJC-1295 half-life is the single most consequential number in the compound’s literature — and the most misunderstood. Published human studies describe a plasma half-life of roughly 6–8 days for the DAC (albumin-binding) form of CJC-1295, versus roughly 30 minutes for the no-DAC form (modified GRF 1-29). That is a difference of more than two orders of magnitude between two compounds that share a name. This guide lays out the CJC-1295 half-life data as reported in published studies: the numbers, the albumin-depot pharmacokinetics behind them, how the two forms compare, and what half-life figures can and cannot tell a researcher. Strict research framing throughout — no dosage information, no administration instructions, no medical advice, no human efficacy claims.

Research-use-only disclaimer: CJC-1295 has never been FDA-approved and is handled as a research compound for laboratory and scientific investigation only. This article is an educational pharmacokinetics overview. It contains no dosage information, no administration instructions, no efficacy claims for humans, and no medical advice.

CJC-1295 Half-Life at a Glance

~6–8 days

Reported plasma half-life, CJC-1295 with DAC (human studies)

~30 minutes

Reported plasma half-life, CJC-1295 without DAC / mod GRF 1-29

Minutes

Native GHRH persistence — the baseline the DAC design was built to beat

Those three figures are the whole story of the CJC-1295 half-life in miniature: a native signal that clears in minutes, a protected scaffold that lasts half an hour, and an albumin-anchored version that persists for days. Everything below explains how the literature arrived at each number — and why the gap between them matters more than any single figure.

Why the DAC Form Lasts Days: Albumin-Depot Pharmacokinetics

The published pharmacokinetic story behind the CJC-1295 half-life of the DAC form is a story about albumin. The Drug Affinity Complex is a maleimidopropionic acid linker attached to a lysine residue of the peptide; published descriptions report that it reacts with the free thiol group of circulating serum albumin — predominantly cysteine-34 — forming a covalent bond. The peptide effectively hitches a ride on one of the most abundant and long-lived proteins in plasma.

The consequences, as described in published summaries, are straightforward: albumin is too large for rapid renal clearance and turns over slowly, so the bound peptide inherits albumin’s persistence rather than its own. The albumin acts as a circulating depot, with biologically active peptide gradually available to engage GHRH receptors over an extended period. Published human studies report detectable activity and sustained GH/IGF-1 axis effects for many days after a single exposure — the pharmacokinetic signature that made the DAC design notable in the first place.

Half-life vs. duration of effect: These are related but distinct. The CJC-1295 half-life figures describe how long the compound persists in plasma; duration of effect describes how long downstream changes (GH exposure, IGF-1 elevation) remain measurable. Published summaries describe IGF-1 remaining elevated well beyond the compound’s own detectable window — a reminder that the pharmacodynamic tail can outlast the pharmacokinetic one.

Scientists working with a microscope in a high-tech laboratory — CJC-1295 half-life study analysis
Photo: Pexels

CJC-1295 Half-Life: DAC vs No-DAC Compared

ParameterCJC-1295 with DACCJC-1295 without DAC (mod GRF 1-29)
Reported plasma half-life~6–8 days (human studies)~30 minutes
Albumin bindingYes — covalent, via maleimidopropionic acid linkerNo significant binding
GH release pattern describedSustained elevation; pulsatility reported preservedBrief, discrete pulses
Downstream IGF-1 elevationDescribed as persisting for days to weeksShort-lived, pulse-linked
Clinical dataPhase I human studies (2006–2009)Limited formal trials
FDA statusNever approvedNever approved

The table makes the practical research point: the two forms are different pharmacokinetic tools. A researcher studying sustained GHRH-receptor activation reaches for the DAC form’s published profile; a researcher studying naturalistic pulsatile signaling reaches for the no-DAC form. Confusing the two CJC-1295 half-life figures — applying the DAC number to the no-DAC compound or vice versa — is the most common error in secondary summaries of this literature.

The CJC-1295 Half-Life in Family Context

The DAC form’s persistence looks most dramatic against its relatives. Published summaries describe the following approximate ranges — all hedged, because assay methods and study designs differ across sources:

  • Native GHRH: minutes — the baseline every analog was designed to improve on.
  • Sermorelin (GHRH 1-29): minutes — the unmodified fragment, described as short-lived in published summaries.
  • CJC-1295 without DAC (mod GRF 1-29): roughly 30 minutes — enzyme-resistant substitutions extend persistence modestly.
  • Tesamorelin: described in published summaries as persisting in the tens of minutes — a full-length GHRH(1-44) analog with an N-terminal fatty-acid modification, approved 2010 for HIV-associated lipodystrophy.
  • CJC-1295 with DAC: roughly 6–8 days — the outlier, by a factor of hundreds, thanks to albumin anchoring.

In this context the CJC-1295 half-life achievement is clear: of all the GHRH-analog strategies published to date, albumin anchoring produced by far the largest persistence gain. It is also clear why the compound attracts both interest and caution — a week-long GHRH signal is pharmacologically unlike anything the native axis produces.

Scientist using a pipette for chemical analysis — CJC-1295 half-life pharmacokinetic research
Photo: Pexels

Myths and Facts About the CJC-1295 Half-Life

Myth: “CJC-1295” has one half-life.

Fact: The name covers two compounds with radically different reported half-lives — roughly 6–8 days with DAC, roughly 30 minutes without. Always check which form a source is describing.

Myth: A longer half-life means a stronger effect.

Fact: Half-life describes persistence, not potency. The published literature describes the DAC form as producing sustained rather than necessarily stronger signaling — and notes that the physiological meaning of week-long GHRH-receptor activation is not established.

Myth: The 6–8 day figure means the compound is active for exactly that long.

Fact: Half-life is the time for plasma concentration to fall by half, not a timer for activity. Published summaries describe downstream IGF-1 effects persisting beyond the compound’s detectable window — the pharmacodynamic tail outlasts the pharmacokinetic curve.

Myth: Half-life data prove the compound works for any particular purpose.

Fact: Pharmacokinetic data describe what the compound does in circulation, not what it achieves. The published human evidence for CJC-1295 is limited to early-phase studies; no large trials and no FDA approval exist. The CJC-1295 half-life literature is a pharmacokinetics story, not an efficacy story.

Reading half-life claims critically: When a secondary source cites a CJC-1295 half-life figure, ask three questions: which form (DAC or no-DAC)? which species (human or animal)? and which source (published study or unsourced summary)? The published human figures — ~6–8 days and ~30 minutes — are the ones with primary literature behind them. Figures outside those ranges usually trace to vendor pages or forums, not studies.

What Half-Life Data Can and Cannot Tell Researchers

Half-life data are genuinely useful — they determine how a compound’s exposure profile looks over time, which is fundamental to interpreting any study that used it. For the CJC-1295 half-life literature, the data tell researchers that DAC-form studies examined sustained receptor activation over days, while no-DAC studies examined brief pulsatile activation. That distinction shapes how every published result should be read.

What the data cannot do is substitute for outcome evidence. Knowing that a compound persists for days says nothing about whether that persistence is beneficial, neutral, or problematic in any context — those are separate empirical questions that the thin human literature on CJC-1295 has not answered. The honest use of CJC-1295 half-life data is as a study-design input and an interpretation aid, not as a proxy for efficacy.

Related Research Reading on This Site

Our other guides cover the same compound from different angles using identical research framing. Start with the What Is CJC-1295? explainer, then read the CJC-1295 Key Research Findings for the measured outcomes. The compound is supplied as CJC-1295 10mg with a lot-specific COA, documented in the COA Library. Compound background is also available at Wikipedia’s CJC-1295 page and primary studies via PubMed.

Scientist in a lab coat using a microscope — CJC-1295 half-life research conclusions
Photo: Pexels

CJC-1295 Half-Life: Key Takeaways

Two compounds, two half-lives, one shared name

The CJC-1295 half-life is roughly 6–8 days with DAC and roughly 30 minutes without — a gap created entirely by the albumin-binding linker. Treating them as one compound is the literature’s most common error; keeping them distinct is the first step to reading any CJC-1295 study correctly. (Research framing only — not a human-use recommendation.)

Persistence is pharmacokinetics, not proof

The DAC form’s days-long persistence is a genuine pharmacokinetic achievement and well described in published studies — but it describes circulation, not outcomes. The human evidence base remains early-phase only, with no approval. Half-life data inform study design; they do not substitute for efficacy evidence. (Research framing only.)

CJC-1295 Half-Life: Final Research Notes

The CJC-1295 half-life story is, at bottom, a story about one chemical trick — bolting a peptide to albumin — and the enormous pharmacokinetic distance that trick covers: from minutes to days in a single design step. Published studies documented the numbers, the depot mechanism, and the downstream persistence of IGF-1 elevation. What they did not do is turn those numbers into outcomes, and the literature is better read for honoring that limit than for crossing it.

For researchers, the half-life figures are tools: they tell you what kind of exposure each form creates, which is exactly what you need to interpret the studies that used them. Kept in that role — interpretation aid, not efficacy proxy — the CJC-1295 half-life data do their job cleanly.

CJC-1295 Half-Life: Frequently Asked Questions

Quick answers about CJC-1295 pharmacokinetics — from published studies, hedged where the literature is hedged.

What is the reported CJC-1295 half-life?

Published human studies report a plasma half-life of roughly 6–8 days for CJC-1295 with DAC (the albumin-binding form) and roughly 30 minutes for CJC-1295 without DAC (modified GRF 1-29). The name covers two compounds — always check which form a source is describing before using a CJC-1295 half-life figure.

Why is the DAC form’s half-life so much longer?

The Drug Affinity Complex — a maleimidopropionic acid linker — covalently binds circulating serum albumin (primarily cysteine-34), creating a circulating depot. Albumin turns over slowly and resists rapid renal clearance, so the bound peptide inherits albumin’s persistence. Published descriptions report the large majority of the DAC-form compound as albumin-bound.

Does a longer half-life mean CJC-1295 is more effective?

No. Half-life describes how long a compound persists in circulation, not its potency or its outcomes. The published literature describes the DAC form as producing sustained rather than necessarily stronger signaling, and the human evidence base is limited to early-phase studies with no FDA approval. Pharmacokinetic data should never be read as efficacy evidence.

How does the CJC-1295 half-life compare to other GHRH analogs?

It is the outlier. Published summaries describe native GHRH and sermorelin as persisting for minutes, modified GRF 1-29 for roughly 30 minutes, and tesamorelin in the tens of minutes — versus roughly 6–8 days for CJC-1295 with DAC. Albumin anchoring produced by far the largest persistence gain of any published GHRH-analog strategy.

How long do downstream effects last after a single exposure?

Published summaries describe IGF-1 elevation persisting well beyond the compound’s own detectable window — the pharmacodynamic tail outlasting the pharmacokinetic curve. Exact durations vary across sources and study designs, so researchers should consult the primary studies (Teichman et al. 2006; Sackmann-Sala et al. 2009) via PubMed rather than relying on secondary figures.

Are the published half-life figures from human or animal studies?

The widely cited figures — roughly 6–8 days (DAC) and roughly 30 minutes (no-DAC) — come from published human studies, principally the 2006–2009 clinical literature. Animal-study figures exist but describe different experimental systems. When evaluating any CJC-1295 half-life claim, confirming the species and the form (DAC vs no-DAC) is the essential first check.

Leave a Comment

Cart0
Cart0

Research Verification Required

This website contains research compounds available exclusively for qualified researchers and laboratory professionals. By entering, you confirm: